Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1CNS 1

Conditions

Melanoma 8Glioma 4Multiple Myeloma 3Thyroid Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Lymphoma 2Lung Neoplasms 2Hematologic Neoplasms 2Glioblastoma 2Colorectal Neoplasms 2Astrocytoma 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Carcinoma, Anaplastic 1Stomach Neoplasms 1Spinocerebellar Degenerations 1Sarcoma 1Refractory Differentiated Thyroid Gland Carcinoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Oligodendroglioma 1Neurofibromatosis 1 1Neurofibroma, Plexiform 1Neurocytoma 1Neuroblastoma 1Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation 1

Interventions

Temozolomide 5Specimen Handling 2Radiotherapy 2Magnetic Resonance Spectroscopy 2vocimagene amiretrorepvec 1trametinib 1dabrafenib 1abexinostat 1Vorinostat 1Transurethral Resection of Bladder 1Surgical Procedures, Operative 1Standard of Care 1Spinal Puncture 1Restraint, Physical 1Radiotherapy, Intensity-Modulated 1Radiation 1Protons 1Proton Therapy 1Practice Guidelines as Topic 1Outcome Assessment, Health Care 1Observational Studies as Topic 1Ketoconazole 1Irinotecan 1Heart Rate 1Granulocyte-Macrophage Colony-Stimulating Factor 1Eflornithine 1Diphtheria-Tetanus Vaccine 1DNA 1Craniotomy 1Carmustine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Oligodendroglioma × dabrafenib × 90 days × Clear all
NCT03975829 2026-06-02

Pediatric Long-Term Follow-up and Rollover Study

Novartis

Phase 4 Recruiting
165 enrolled
CNSMyeloid

Astrocytoma, Ganglioneuroma, Glioblastoma, Glioma, Histiocytosis, Langerhans-Cell, Neuroblastoma, Neurofibromatosis 1, Oligodendroglioma, Ganglioglioma, Neurocytoma, Neurofibroma, Plexiform

Data powered by HemOnc (CC BY 4.0) Colophon âš¡